Safety and Tolerance of Increased Doses of HRS-1780 Tablets in Healthy Subjects
Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled phase I clinical study. The primary
objective is to evaluate the safety, tolerability, PK, and PD of single- and multiple-dose
HRS-1780 in healthy subjects, and to evaluate the food effect on PK of HRS-1780.